IXICO says it is excited as Huntington’s consortium progresses
“We're excited to support this important project in our endeavour to bring novel imaging biomarkers into clinical trials," said Robin Wolz, IXICO chief scientific officer
Company
IXICO PLC
LON:IXI
IXICO is no ordinary Imaging Contract Research Organisation (iCRO). By unlocking valuable insights into drug safety and efficacy, IXICO has built a highly respected global reputation and a 20-year track record as an end-to-end iCRO. IXICO addresses the complex biomarker challenges associated with neurodegenerative conditions, expertly managing and analysing neuroimaging clinical trials in areas such as Alzheimer’s, Parkinson’s, Huntington's and other rare diseases.
263 stories · page 4 of 14
IXICO raises profit guidance after strong second half
Orders are expected to top £15mln at the year-end
IXICO wins contract for phase 2 Parkinson's disease trial
The contract, signed with a leading European biopharmaceutical company, is the second study award with this client in the last 12 months
IXICO PLC expects strong second half; flags clinical trial impact
The neuro-imaging expert provided a trading statement alongside its interim results
IXICO lands its third Huntington’s Disease contract in two months
The latest commercial agreement is worth around £900,000
IXICO says first half represents period of consolidation
Chief executive Giulio Cerroni said he was "satisfied" with the performance over the past six months, delivering positive EBITDA and operating cash despite the halting of several important client trials
IXICO lands £800,000 Huntington's contract
It will support a global observational study to assess participants for the early detection of the condition
IXICO wins £800,000 Huntington's disease trial
This trial, which is expected to run for over five years, is the company's second study for the client after winning a 2021 contract following a Multiple System Atrophy study
IXICO hails the introduction of IXIQ.Ai, its new brain imaging technology
The new platform has been developed and validated in collaboration with academic and pharma partners, the company said
Ixico names Dr Lynne Hughes as senior therapeutic advisor
She most recently held a position at date science company IQVIA
IXICO to focus on trials framework as dementia collaboration enters second phase
Dementias Platform UK (DPUK) is an industry and academic collaborative body focused on finding ways to treat and prevent the disease
IXICO names new non-executive director
Rogers previously held senior positions at GlaxoSmithKline
IXICO reports 34% EBITDA growth and looks forward to new launches
In the current year the board is managing the challenges from the recent halt of a clinical trial and pursuing a focused investment programme
IXICO inks neuroimaging deal for phase III demyelinating disorder study
The trial will be conducted across 100 sites in 10 countries and is worth more than £1.0mln over seven years
IXICO says client suspends trial while it gathers more pre-clinical data
IXICO has been notified by a client of an indefinite halt to the client's clinical trial following the receipt of unexpected preclinical data.
IXICO boosted by strong end to financial year
“With an ageing population and the high unmet clinical need for new treatments for neurodegenerative diseases we remain very confident in the medium- and long-term opportunity"
IXICO lands US$750,000, two-year deal with top-five contract research group
The company will support a phase II Alzheimer's trial
IXICO lands Huntington’s disease clinical trial contract worth more than US$500,000
The latest deal is with an unnamed existing client
IXICO to provide expertise in clinical trial for nervous system disease treatment
The contract is worth more than US$500,000 over four years, investors were told
IXICO expects revenues to recover as Covid disruption eases
"We anticipate returning to a double-digit revenue growth trajectory as our 2022 financial year progresses”